Mouse 4T1 breast tumor model.
Pulaski BA, Ostrand-Rosenberg S.
Curr Protoc Immunol. 2001 May;Chapter 20:Unit 20.2. doi: 10.1002/0471142735.im2002s39.
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.
Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, Méndez Romero A, Nevens D, Palma D, Park C, Ricardi U, Scorsetti M, Yu J, Woodward WA.
Radiother Oncol. 2020 Jul;148:157-166. doi: 10.1016/j.radonc.2020.04.003. Epub 2020 Apr 22.
Multiple lesions of the spleen: differential diagnosis of cystic and solid lesions.
Kamaya A, Weinstein S, Desser TS.
Semin Ultrasound CT MR. 2006 Oct;27(5):389-403. doi: 10.1053/j.sult.2006.06.004.
Glucocorticoids promote breast cancer metastasis.
Obradović MMS, Hamelin B, Manevski N, Couto JP, Sethi A, Coissieux MM, Münst S, Okamoto R, Kohler H, Schmidt A, Bentires-Alj M.
Nature. 2019 Mar;567(7749):540-544. doi: 10.1038/s41586-019-1019-4. Epub 2019 Mar 13.
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C.
N Engl J Med. 2012 Mar 8;366(10):883-892. doi: 10.1056/NEJMoa1113205.
Decoding the interplay between genetic and non-genetic drivers of metastasis.
Karras P, Black JRM, McGranahan N, Marine JC.
Nature. 2024 May;629(8012):543-554. doi: 10.1038/s41586-024-07302-6. Epub 2024 May 15.
CECR2 drives breast cancer metastasis by promoting NF-kappaB signaling and macrophage-mediated immune suppression.
Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L, Rimm DL, Yin M, Yan Q.
Sci Transl Med. 2022 Feb 2;14(630):eabf5473. doi: 10.1126/scitranslmed.abf5473. Epub 2022 Feb 2.
The evolutionary history of lethal metastatic prostate cancer.
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC; ICGC Prostate Group; Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS.
Nature. 2015 Apr 16;520(7547):353-357. doi: 10.1038/nature14347. Epub 2015 Apr 1.
Metabolic control of cancer metastasis: role of amino acids at secondary organ sites.
Karno B, Edwards DN, Chen J.
Oncogene. 2023 Nov;42(47):3447-3456. doi: 10.1038/s41388-023-02868-3. Epub 2023 Oct 18.
The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer.
Wang R, Zhu Y, Liu X, Liao X, He J, Niu L.
BMC Cancer. 2019 Nov 12;19(1):1091. doi: 10.1186/s12885-019-6311-z.
